Rezolute, Inc. (RZLT)
Market Cap | 216.34M |
Revenue (ttm) | n/a |
Net Income (ttm) | -58.21M |
Shares Out | 51.39M |
EPS (ttm) | -1.14 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 259,509 |
Open | 4.310 |
Previous Close | 4.310 |
Day's Range | 4.160 - 4.440 |
52-Week Range | 0.720 - 6.100 |
Beta | 1.31 |
Analysts | Strong Buy |
Price Target | 9.67 (+129.69%) |
Earnings Date | May 15, 2024 |
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as Ant... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price forecast is $9.67, which is an increase of 129.69% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/s/v/press14-2499573.jpg)
Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
Additional $6.7M in funding resulting in approximately $67M in gross proceeds Additional $6.7M in funding resulting in approximately $67M in gross proceeds
![](https://cdn.snapi.dev/images/v1/y/h/press5-2492556.jpg)
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies ...
![](https://cdn.snapi.dev/images/v1/j/b/press18-2479174.jpg)
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies ...
![](https://cdn.snapi.dev/images/v1/c/a/press12-2478732.jpg)
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies ...
![](https://cdn.snapi.dev/images/v1/w/h/conf6-2453472.jpg)
Rezolute to Participate in the Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transforma...
![](https://cdn.snapi.dev/images/v1/7/s/press20-2442393.jpg)
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease in...
![](https://cdn.snapi.dev/images/v1/c/y/press14-2433277.jpg)
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
![](https://cdn.snapi.dev/images/v1/d/0/press14-2385139.jpg)
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transfor...
![](https://cdn.snapi.dev/images/v1/s/w/press5-2310576.jpg)
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) Potential to more than double the addr...
![](https://cdn.snapi.dev/images/v1/n/g/press17-2274481.jpg)
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
![](https://cdn.snapi.dev/images/v1/k/g/press4-2242107.jpg)
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
![](https://cdn.snapi.dev/images/v1/c/m/press10-2240017.jpg)
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
![](https://cdn.snapi.dev/images/v1/y/b/press19-2196094.jpg)
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 Company anticipates completing enrollment by the end of 2024 and reporting topline results i...
![](https://cdn.snapi.dev/images/v1/n/y/press3-2194355.jpg)
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
![](https://cdn.snapi.dev/images/v1/s/p/press19-2170850.jpg)
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday Biotech Sale: 12 Stocks for XBI-MAS." Despite overall m...
![](https://cdn.snapi.dev/images/v1/m/o/press12-2163077.jpg)
Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day
REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
![](https://cdn.snapi.dev/images/v1/u/v/press13-2155463.jpg)
Rezolute Reports First Quarter Fiscal 2024 Results
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
![](https://cdn.snapi.dev/images/v1/f/u/press10-2106292.jpg)
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism PRIME eligibility granted based on key positive data fr...
![](https://cdn.snapi.dev/images/v1/n/z/press2-2098479.jpg)
Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism
REDWOOD CITY, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
![](https://cdn.snapi.dev/images/v1/a/v/press12-2064406.jpg)
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023
![](https://cdn.snapi.dev/images/v1/h/e/conf4-2050863.jpg)
Rezolute to Participate in Upcoming Investor Conferences in September
REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t...
![](https://cdn.snapi.dev/images/v1/j/t/press5-1950405.jpg)
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m. ET REDWOOD CITY, Calif.
![](https://cdn.snapi.dev/images/v1/z/g/press6-1917186.jpg)
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innov...
![](https://cdn.snapi.dev/images/v1/n/y/press16-1886232.jpg)
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023
![](https://cdn.snapi.dev/images/v1/p/z/press10-1810692.jpg)
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye RZ402 is an oral therapy being developed as a potential alternati...